Neurogene board panel approves Nasdaq Rule 5635 inducement stock option grants
Neurogene said its Compensation Committee approved non-qualified stock option inducement grants under Nasdaq Listing Rule 5635(c)(4).
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock opt…